| Activitatea profesională |
2015-prezent: Cercetator principal II, Departamentul de Genomica Functionala, Proteomica si Patologie Experimentala, Institutul Oncologic “Prof Dr. Ion Chiricuta”, Cluj-Napoca, Romania.
2006-2015: PI, Coordonator de programe nationale de cercetare in patologia tumorala (col uterin, san, prostata, colon); Implementarea tehnologiilor de microarray (Agilent), PCR array si qRT-PCR in cadrul Departamentului de Genomica Functionala. Studii de genomica functionala, farmacogenomica si hemogenomica in patologia maligna; teste oncogenetce: K-Ras, BCR-ABL.
1996-2006-Chimist, Departamentul de Genomica Functionala, Proteomica si Patologie Experimentala, Institutul Oncologic “Prof Dr. Ion Chiricuta”, Cluj-Napoca, Romania.
August -Noimebrie 2015: training in DNA methylation, The Ohio State University Comprehensive Cancer, USA
Aprilie 2003-Mai 2004: Bursier Marie Curie (QLGA-1999-50406) Unitatea de Genomica Functionala, Institutul Gustave Roussy, Villejuif, Franta.
Aprilie-Iunie 2002: bursier in Laboratorul de Radiosensibilitate Tumorala (UPRES EA27-10), Institutul Gustave Roussy, Villejuif, Franta.
Experienţă de formator:
2011-2013: Coordonator tematic la un curs de formare de specialisti, Proiect POSDRU/81/3.2/S/58819, Tehnici de diagnostic molecular ca suport al diagnosticului clinic.(120 cursanti) |
| Publicaţii: |
Articole originale (selectie):
1. Neamtiu IA, Bloom MS, Dumitrascu I, Roba CA, Pop C, Ordeanu C, Balacescu O, Gurzau ES. Impact of exposure to tobacco smoke, arsenic, and phthalates on locally advanced cervical cancer treatment-preliminary results. PeerJ. 2016 Sep 8;4:e2448. doi: 10.7717/peerj.2448. eCollection 2016.
2. Balacescu O, Balacescu L, Virtic O, Visan S, Gherman C, Drigla F, Pop L, Bolba-Morar G, Lisencu C, Fetica B, Tudoran O, Berindan-Neagoe I. Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients. Mediators Inflamm. 2016;2016:3239167. doi:10.1155/2016/3239167. Epub 2016 Jan13.
3. Grozav A, Balacescu O, Balacescu L, Cheminel T, Berindan-Neagoe I, Therrien B. Synthesis, Anticancer Activity, and Genome Profiling of Thiazolo Arene Ruthenium Complexes. J Med Chem. 2015 Nov 12;58(21):8475-90. doi: 10.1021/acs.jmedchem.5b00855. Epub 2015 Oct 30. PubMed PMID: 26488797.
4. Tudoran O, Virtic O, Balacescu L, Lisencu C, Fetica B, Gherman C, Balacescu O, Berindan-Neagoe I. Baseline blood immunological profiling differentiates between Her2-breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response. Onco Targets Ther. 2015 Nov 18;8:3415-23. doi: 10.2147/OTT.S91720. eCollection 2015.
5. Belean B, Borda M, Ackermann J, Koch I, Balacescu O. Unsupervised image segmentation for microarray spots with irregular contours and inner holes. BMC Bioinformatics. 2015 Dec 23;16:412. doi: 10.1186/s12859-015-0842-3.
6. Tudoran OM, Soritau O, Balacescu L, Pop L, Meurice G, Visan S, Lindberg S, Eniu A, Langel U, Balacescu O, Berindan-Neagoe I. PDGF beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation. J Cell Mol Med. 2014 Oct 14. doi: 10.1111/jcmm.12449.
7. Balacescu O, Balacescu L, Tudoran O, Todor N, Rus M, Buiga R, Susman S, Fetica B, Pop L, Maja L, Visan S, Ordeanu C, Berindan-Neagoe I, Nagy V. Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure. BMC Cancer. 2014 Apr 8;14:246. doi: 10.1186/1471-2407-14-246.
8. Virag P, Fischer-Fodor E, Perde-Schrepler M, Brie I, Tatomir C, Balacescu L, Berindan-Neagoe I, Victor B, Balacescu O. Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins. BMC Genomics. 2013 Jul 16;14:480. doi: 10.1186/1471-2164-14-480.
9. Jude C, Dejica D, Samasca G, Balacescu L, Balacescu O. Soluble CD163 serum levels are elevated and correlated with IL-12 and CXCL10 in patients with long-standing rheumatoid arthritis. Rheumatol Int. 2013 Apr;33(4):1031-7
10. Tudoran O, Soritau O, Balacescu O, Balacescu L, Braicu C, Rus M, Gherman C, Virag P, Irimie F, Berindan-Neagoe I. Early transcriptional pattern of angiogenesis induced by EGCG treatment in cervical tumour cells. J Cell Mol Med. 2012 Mar;16(3):520-30.
11. Berindan-Neagoe I, Braicu C, Tudoran O, Balacescu O, Irimie A. Early apoptosis signals induced by a low dose of epigallocatechin 3-gallate interfere with apoptotic and cell death pathways. J NanosciNanotechnol. 2012 Mar;12(3):2113-9.
12. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006 Apr 5;98(7):472-82
Review-uri (selectie):
1. Gavrilas LI, Ionescu C, Tudoran O, Lisencu C, Balacescu O, Miere D. The Role of Bioactive Dietary Components in Modulating miRNA Expression in Colorectal Cancer. Nutrients. 2016 Sep 26;8(10).
2. Tudoran OM, Balacescu O, Berindan-Neagoe I. Breast cancer stem-like cells: clinical implications and therapeutic strategies. Clujul Med. 2016;89(2):193-8. doi: 10.15386/cjmed-559. Epub 2016 Apr 15. Review.
3. Manzat-Saplacan RM, Mircea PA, Balacescu L, Chira RI, Berindan-Neagoe I, Balacescu O. Can we change our microbiome to prevent colorectal cancer development? Acta Oncol. 2015;54(8):1085-95.
4. Miron N, Susman S, Balacescu O, Buiga R, Berindan-Neagoe I, Cristea V, Balacescu L, Manolescu V, Ciuleanu TE. Novel cellular and molecular approaches to stratification and treatment of colorectal cancer. J Gastrointestin Liver Dis.2012 Dec;21(4):413-21.
5. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol. 2009;48(6):811-21. |